(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/184315 A1

(51) International Patent Classification:
*A61K 47/68* (2017.01) *A61P 5/48* (2006.01)
*A61P 3/08* (2006.01)

(21) International Application Number:
PCT/US2025/017549

(22) International Filing Date:
27 February 2025 (27.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/559,342 29 February 2024 (29.02.2024) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: **FALSEY, James, R.**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US). **WU, Bin**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US). **LU, Shu-Chen**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US). **SHAM, Kelvin, K.C.**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US). **CHENG, Yuan**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US). **MIRANDA, Leslie, P.**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US). **VENIANT-ELLISON, Murielle, Marie**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US). **ARAL, Jennifer**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(74) Agent: **MADL, Amy, C.**; c/o Amgen INC., One Amgen Center Drive, Law Dept. - Patent Operations, M/S 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: GLUCAGON RECEPTOR AGONISTS, CONJUGATED TO GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANTIBODIES





FIG. 8A

(57) Abstract: Disclosed herein are polypeptides having activity as agonists of a glucagon receptor ("GCGR"), molecules comprising such polypeptides and molecules comprising an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor ("GIPR"), pharmaceutical compositions comprising such polypeptides and molecules, and methods of using such polypeptides, molecules, and pharmaceutical compositions in weight management and the treatment of certain disorders such as obesity.

[Continued on next page]

WO 2025/184315 A1

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*